Log in

NASDAQ:MNOV - MediciNova Stock Price, Forecast & News

$3.28
-0.10 (-2.96 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$3.10
Now: $3.28
$3.49
50-Day Range
$2.90
MA: $4.53
$6.16
52-Week Range
$2.79
Now: $3.28
$13.37
Volume206,800 shs
Average Volume182,131 shs
Market Capitalization$144.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Read More
MediciNova logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.71 per share

Profitability

Net Income$-12,940,000.00

Miscellaneous

Employees9
Market Cap$144.19 million
Next Earnings Date4/1/2020 (Estimated)
OptionableOptionable

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.


MediciNova (NASDAQ:MNOV) Frequently Asked Questions

How has MediciNova's stock been impacted by COVID-19 (Coronavirus)?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MNOV stock has decreased by 0.3% and is now trading at $3.28. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MediciNova.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Wednesday, April 1st 2020. View our earnings forecast for MediciNova.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.04. View MediciNova's earnings history.

What price target have analysts set for MNOV?

1 analysts have issued 1 year target prices for MediciNova's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate MediciNova's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 235.4% from the stock's current price. View analysts' price targets for MediciNova.

Has MediciNova been receiving favorable news coverage?

News stories about MNOV stock have trended extremely negative recently, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. MediciNova earned a news impact score of -4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutMediciNova.

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

Who are MediciNova's key executives?

MediciNova's management team includes the following people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
  • Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
  • Ms. Carla Reyes, Chief Financial Officer (Age 47)
  • Mr. John O'Neil CPA, Controller

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (1.73%), Geode Capital Management LLC (1.23%), Bank of New York Mellon Corp (0.36%), Charles Schwab Investment Management Inc. (0.23%), California Public Employees Retirement System (0.19%) and Goldman Sachs Group Inc. (0.13%). Company insiders that own MediciNova stock include Kazuko Matsuda and Yuichi Iwaki. View institutional ownership trends for MediciNova.

Which institutional investors are selling MediciNova stock?

MNOV stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. View insider buying and selling activity for MediciNova.

Which institutional investors are buying MediciNova stock?

MNOV stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, UBS Group AG, California Public Employees Retirement System, Barclays PLC, Marshall Wace LLP, Bank of America Corp DE, State Street Corp, and Goldman Sachs Group Inc.. Company insiders that have bought MediciNova stock in the last two years include Kazuko Matsuda, and Yuichi Iwaki. View insider buying and selling activity for MediciNova.

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $3.28.

How big of a company is MediciNova?

MediciNova has a market capitalization of $144.19 million. The biopharmaceutical company earns $-12,940,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe. View additional information about MediciNova.

What is MediciNova's official website?

The official website for MediciNova is http://medicinova.com/.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]


MarketBeat Community Rating for MediciNova (NASDAQ MNOV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  200 (Thanks for Voting!)
Underperform Votes:  174 (Thanks for Voting!)
Total Votes:  374
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel